These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37919692)

  • 21. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
    Leonardi A; Flamion B; Baudouin C
    Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporine 0.09% solution (Cequa) for dry eye Disease.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):116-118. PubMed ID: 31381551
    [No Abstract]   [Full Text] [Related]  

  • 23. Real-world insights and outcomes related to ciclosporin A 0.1% cationic emulsion for the long-term treatment of dry eye disease in Germany: Country-level sub-analysis of the PERSPECTIVE study.
    Lanzl I; Deuter CME; Lorenz K; Geerling G;
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct; 262(10):3261-3271. PubMed ID: 38722320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
    Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
    J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
    Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
    Schechter BA; Urbieta M; Bacharach J; Toyos M; Smyth-Medina R; Mitchell B; Luchs JI
    Clin Ophthalmol; 2022; 16():4145-4151. PubMed ID: 36536927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
    Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
    Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The place of ciclosporin A cationic emulsion 0.1% in the therapy of xerophthalmia].
    Maychuk DY; Yani EV; Brzheskiy VV; Grishina EE; Drozdova EA; Maychuk NV; Panova IE; Safonova TN
    Vestn Oftalmol; 2024; 140(2):102-111. PubMed ID: 38742506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
    Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
    Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.
    Sacchetti M; Mantelli F; Lambiase A; Mastropasqua A; Merlo D; Bonini S
    Br J Ophthalmol; 2014 Aug; 98(8):1016-22. PubMed ID: 24344232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials.
    Leonardi A; Doan S; Aragona P; Amrane M; Ismail D; Montero J; Németh J; Bremond-Gignac D
    Eye (Lond); 2023 Aug; 37(11):2320-2326. PubMed ID: 36564576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease.
    Burade V; Zalawadia R; Patel A; Ogundele A
    Clin Ophthalmol; 2020; 14():2747-2755. PubMed ID: 33061257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
    White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
    [No Abstract]   [Full Text] [Related]  

  • 35. Perfluorohexyloctane ophthalmic solution (Miebo) for dry eye disease.
    Med Lett Drugs Ther; 2024 Jan; 66(1694):13-14. PubMed ID: 38212258
    [No Abstract]   [Full Text] [Related]  

  • 36. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
    Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
    Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
    Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
    JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease.
    Tuan HI; Chi SC; Kang YN
    Drug Des Devel Ther; 2020; 14():265-274. PubMed ID: 32021110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease.
    Locatelli EVT; Acuna KA; Betz J; Tovar AA; Galor A
    Cornea; 2024 Jan; 43(1):88-94. PubMed ID: 36853599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.